Genomic biomarkers in predictive medicine: An interim analysis

EMBO Molecular Medicine

Volumn 3, Issue 8, 2011, Pages 429-435

  Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; Early detection; Genomics; Personalized medicine; Translational research

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IMATINIB;

ARTICLE; ATYPICAL CHRONIC MYELOID LEUKEMIA; CARCINOGENESIS; CHRONIC DISEASE; COLORECTAL CANCER; DISEASE COURSE; DNA POLYMORPHISM; FOLLOW UP; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOMICS; HUMAN; LUNG NON SMALL CELL CANCER; OVARY CANCER; POINT MUTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SICKLE CELL ANEMIA;

EARLY DIAGNOSIS; GENETIC MARKERS; GENETIC TESTING; GENOME, HUMAN; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 79960953818     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201100153     Document Type: Article

References (30)

1. Ashworth A, Lord CJ, Reis-Filho JS (2011) Genetic interactions in cancer progression and treatment. Cell 145: 30-38
2. Begley S (2008) We fought cancer.. and cancer won. Newsweek, Sep 15, 43-66
3. Bloss CS, Schork NJ, Topol EJ (2011) Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med 364: 524-534
4. Bucher L (2011) Missing the mark: Why is it so hard to find a test to predict cancer? Nature 471: 428-432
5. Butler D (2008) Crossing the valley of death. Nature 453: 840-842
6. Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, Goodhead I, Follows GA, Green AR, Futreal PA, Stratton MR (2008) Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci 105: 13081-13086
7. Drucker B, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, et al (2001) Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037
8. Etzioni R, Urban N, Ramsey S, Mcintosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L (2003) The case for early detection. Nat Rev Cancer 3: 1-10
9. Flaherty KT, Puzanov I, Kim KB, Ribas A, Mcarthur GA, Sosman JA, O'dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819
10. Haber DA, Gray NS, Baselga J (2011) The evolving war on cancer. Cell 145: 19-24
11. Hawk ET, Matrisian LM, Nelson WG, Dorfman GS, Stevens L, Kwok J, Viner J, Hautala J, Grad O (2008) The translational research working group developmental pathways: Introduction and overview. Clin Cancer Res 14: 5664-5671
12. Ioannidis JPA, Castaldi P, Evangelou E (2010) A compendium of genome-wide associations for cancer: critical synopsis and reappraisal. J Natl Cancer Inst 102: 846-858
13. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, et al (2008) Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci 105: 4283-4288
14. Jonkers J, Berns A (2004) Oncogene addiction. Cancer Cell 6: 535-538
15. Kraft P, Halman CA (2010) GWAS identifies a common breast cancer risk allele among BRCA1 carriers. Nat Genet 42: 819-820
16. Kwak EL, Bang YJ, Camidge R, Shaw AT, Solomon B, Maki RG, Ou SHI, Dezube BJ, Janne PA, Costa DB, et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 693-703
17. Lander ES (2011) Initial impact of the sequencing of the human genome. Nature 470: 187-213
18. Ledford H (2010) The cancer genome challenge. Nature 464: 972-974
19. Mai PL, Wentzensen N, Greene MH (2011) Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev Res 4: 303-306
20. Nathan DG, Varmus HE (2000) The National Institutes of Health and clinical research: a progress report. Nat Med 6: 1201-1204
21. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, mcindoo J, Cook K, Stepansky A, Levy D, Esposito D, et al (2011) Tumor evolution inferred by single-cell sequencing. Nature 472: 90-94
22. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826
23. Pauling L, Itano HA, Singer SJ, Wells IC (1949) Sickle cell anemia, a molecular disease. Science 25: 543-548
24. Perou CM, Sorlie T, Eisen MB, van De Rijn M, Jeffrey SS, Reese CA, Pollak JR, Ross DT, Jonsen H, Akslen LA, et al (2000) Molecular portraits of human breast tumors. Nature 406: 747-752
25. Simon R (2010) Translational research in oncology: key bottlenecks and new paradigms. Expert Rev Mol Med 12: e32
26. Subramanian J, Simon R (2010) Gene expression based prognostic signatures in lung cancer: Ready for clinical use? J Natl Cancer Inst 102: 464-474
27. Sung NS, Crowley WF, Genel M, Salber P, Sandy L, Herwood LM, Johnson SB, Catanese V, Tilson H, Getz K (2003) Central challenges facing the national clinical research enterprise. J Am Med Assoc 289: 1278-1287
28. Van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009
29. Weinstein IB (2002) Addiction to oncogenes-the Achilles heel of cancer. Science 297: 63-64
30. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RF, Urban N, Mor G, Bast RC, Moor LE, et al (2011) A framework for evaluating biomarkers for early detction: validation of biomarker panels for ovarian cancer. Cancer Prev Res 4: 375-383